NEW YORK, Nov. 9, 2015 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug (IND) application for its first in class, lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP). This …